for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Axcella Health Inc

AXLA.OQ

Latest Trade

3.05USD

Change

-0.18(-5.57%)

Volume

2,665

Today's Range

3.05

 - 

3.13

52 Week Range

2.98

 - 

6.84

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Axcella Reports Q1 Loss Per Share $0.40

May 6 (Reuters) - Axcella Health Inc <AXLA.O>::AXCELLA REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 LOSS PER SHARE $0.40.EXPECTS ITS CASH BALANCE WILL BE SUFFICIENT TO MEET CO'S OPERATING NEEDS INTO Q3 OF 2022.AXCELLA HEALTH - AS OF MARCH 31, 2021, CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES TOTALED $93.0 MILLION VERSUS $107.3 MILLION AT DECEMBER 31, 2020.

Axcella Reports Fourth Quarter And Full Year 2020 Financial Results And Provides Business Update

March 17 (Reuters) - Axcella Health Inc <AXLA.O>::AXCELLA REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 LOSS PER SHARE $0.40.Q4 EARNINGS PER SHARE ESTIMATE $-0.36 -- REFINITIV IBES DATA.INITIATION OF AXA1665 PHASE 2 CLINICAL TRIAL IN OHE EXPECTED IN Q2 2021.INITIATION OF AXA1125 PHASE 2B CLINICAL TRIAL IN NASH EXPECTED IN Q2 2021.

Axcella Announces Ind Clearance For Axa1665, Program Updates And 2021 Milestones

Jan 11 (Reuters) - Axcella Health Inc <AXLA.O>::AXCELLA ANNOUNCES IND CLEARANCE FOR AXA1665, PROGRAM UPDATES AND 2021 MILESTONES.AXCELLA HEALTH INC - AXA1665 PHASE 2 TRIAL INITIATION PLANNED FOR Q2.AXCELLA HEALTH INC - AXA1125 PHASE 2B TRIAL INITIATION PLANNED FOR Q2.AXCELLA HEALTH INC - COMPANY DECIDES NOT TO EXPAND ENROLLMENT IN AXA4010-001 FOLLOWING COHORT 1 READOUT.AXCELLA HEALTH INC - PIPELINE EXPANSION OPPORTUNITIES TO BE ANNOUNCED IN 2021.

Axcella Reports Q3 Loss Per Share $0.34

Nov 12 (Reuters) - Axcella Health Inc <AXLA.O>::AXCELLA REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.AXCELLA HEALTH INC - QTRLY LOSS PER SHARE $0.34.AXCELLA HEALTH INC - PHASE 2B SERIAL BIOPSY CLINICAL TRIAL ENROLLING ADULT PATIENTS WITH NASH EXPECTED TO BE INITIATED IN FIRST HALF OF 2021.AXCELLA HEALTH INC - PHASE 2 CLINICAL TRIAL ENROLLING SUBJECTS WITH LIVER CIRRHOSIS EXPECTED TO BE INITIATED IN FIRST HALF OF 2021.AXCELLA HEALTH INC - EXPECTS TO COMMUNICATE DECISION WHETHER TO ENROLL ADDITIONAL SUBJECTS WITH SICKLE CELL DISEASE IN AXA4010-001 STUDY BY EARLY 2021.

Axcella Announces Pricing Of Public Offering Of Common Stock

May 13 (Reuters) - Axcella Health Inc <AXLA.O>::AXCELLA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 11.0 MILLION COMMON SHARES PRICED AT $4.75PER SHARE.

Axcella Health Inc Files For Offering Of Up To 11.0 Mln Shares Of Common Stock

May 11 (Reuters) - Axcella Health Inc <AXLA.O>::AXCELLA HEALTH INC FILES FOR OFFERING OF UP TO 11.0 MILLION SHARES OF COMMON STOCK - SEC FILING.

Axcella Reports Q1 Loss Per Share Of $0.65

May 11 (Reuters) - Axcella Health Inc <AXLA.O>::AXCELLA REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 LOSS PER SHARE $0.65.Q1 EARNINGS PER SHARE ESTIMATE $-0.86 -- REFINITIV IBES DATA.AXCELLA HEALTH - REPORTED POSITIVE TOP-LINE DATA FROM AXA1125-003.COMPLETED ENROLLMENT OF AXA1665-002, WITH DATA READOUT EXPECTED IN Q3 2020.EXPECTS CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO MEET COMPANY'S OPERATING NEEDS INTO Q2 OF 2021.

Axcella Announces Positive Top-Line Data From AXA1125-003 Clinical Study Showing Multifactorial Activity In Adult Subjects With NAFLD

May 6 (Reuters) - Axcella Health Inc <AXLA.O>::AXCELLA ANNOUNCES POSITIVE TOP-LINE DATA FROM AXA1125-003 CLINICAL STUDY SHOWING MULTIFACTORIAL ACTIVITY IN ADULT SUBJECTS WITH NAFLD.AXCELLA HEALTH INC - GREATER ACTIVITY IN KEY MARKERS SEEN AMONG SUBJECTS WITH TYPE 2 DIABETES RECEIVING AXA1125.AXCELLA HEALTH - PLANS TO ENGAGE WITH FDA ABOUT IND SUBMISSION FOR AXA1125, PROPOSED PHASE 2B CLINICAL TRIAL IN ADULT NASH & PEDIATRIC DEVELOPMENT PROGRAM.AXCELLA HEALTH INC - RESULTS FROM STUDY SHOWED THAT AXA1125 AND AXA1957 WERE GENERALLY WELL-TOLERATED.AXCELLA HEALTH - STUDY SHOWED SUSTAINED REDUCTIONS FOR AXA1125 AND AXA1957 VERSUS PLACEBO IN KEY BIOMARKERS OF METABOLISM, INFLAMMATION & FIBROSIS OVER 16 WEEKS.AXCELLA HEALTH - OVERALL, COMPARED TO PLACEBO, AXA1125 SHOWED LARGER AND MORE CONSISTENT REDUCTIONS IN CLINICALLY RELEVANT BIOMARKERS THAN AXA1957.AXCELLA HEALTH - TWO SERIOUS ADVERSE EVENTS WERE REPORTED IN AXA1125 & AXA1957 STUDY, BOTH DETERMINED TO BE UNRELATED TO STUDY PRODUCT ADMINISTRATION.AXCELLA HEALTH - DECIDED THAT WE WILL NOT REINITIATE AXA1957-002 PEDIATRIC STUDY, WHICH HAD RECENTLY BEEN SUSPENDED DUE TO COVID-19.

Axcella Health Q4 Loss Per Share $0.68

Axcella Health Inc <AXLA.O>::AXCELLA REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 LOSS PER SHARE $0.68.Q4 EARNINGS PER SHARE ESTIMATE $-0.74 -- REFINITIV IBES DATA.AXCELLA HEALTH - ON TRACK TO REPORT TOP-LINE DATA FOR LEAD CANDIDATES FOR NONALCOHOLIC STEATOHEPATITIS, OVERT HEPATIC ENCEPHALOPATHY IN MID-2020.AXCELLA HEALTH - CASH AND CASH EQUIVALENTS AT DEC 31, 2019 WERE $92.1 MILLION, WHICH COMPARES WITH $79.5 MILLION AT DEC 31, 2018.AXCELLA HEALTH - ENROLLMENT AND DOSING IN AXA1957 PEDIATRIC CLINICAL STUDY HAS BEEN TEMPORARILY SUSPENDED.CONTINUES TO VIEW PEDIATRIC NASH AS A SIGNIFICANT AREA OF UNMET NEED.EXPECTS CASH, EQUIVALENTS WILL BE SUFFICIENT TO MEET OPERATING NEEDS INTO Q2 OF 2021.

Axcella Health Reports Third Quarter Results

Nov 12 (Reuters) - Axcella Health Inc <AXLA.O>::AXCELLA HEALTH REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.Q3 LOSS PER SHARE $0.75.Q3 EARNINGS PER SHARE ESTIMATE $-0.71 -- REFINITIV IBES DATA.CLOSED Q3 WITH $105 MILLION IN CASH AND CASH EQUIVALENTS, PROVIDING RUNWAY THROUGH Q2 OF 2021.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up